Find a Clinical Trial

Find a Clinical Trial

Search by practice name, trial titles, indicators and specific disease types.

Urothelial Cancer

Clinical Trial at: Texas Oncology - Rockwall

A single-arm, open-label, multicenter study of enfortumab vedotin (ASG-22CE) for treatment of patients with locally advanced or metastatic urothelial cancer who previously received immune checkpoint inhibitor (CPI) therapy - SGN22E-001

  • Details

ClinicalTrials.gov ID: NCT03219333
Diagnosis Type: NA
USOR Number: 17005

  • Practice Details

3144 Horizon Rd, Suite 110
Rockwall, Texas 75032
293.39 mi. away
P: (972) 771-3322

More Details View Practice Page

Myelofibrosis

Clinical Trial at: Texas Oncology - Rockwall

INCB 39110-209, An Open-Label Phase 2 Study of Itacitinib (INCB039110) in Combination With Low-Dose Ruxolitinib or Itacitinib Alone Following Ruxolitinib in Subjects With Myelofibrosis

  • Details

ClinicalTrials.gov ID: NCT03144687
Diagnosis Type: NA
USOR Number: 17085

  • Practice Details

3144 Horizon Rd, Suite 110
Rockwall, Texas 75032
293.39 mi. away
P: (972) 771-3322

More Details View Practice Page

Prostate Cancer

Clinical Trial at: Texas Oncology - Rockwall

TRITON2: A Multicenter, Open-label Phase 2 Study of Rucaparib in Patients with Metastatic Castration-resistant Prostate Cancer Associated with Homologous Recombination Deficiency - CO-338-052

  • Details

ClinicalTrials.gov ID: NCT02952534
Diagnosis Type: NA
USOR Number: 16237

  • Practice Details

3144 Horizon Rd, Suite 110
Rockwall, Texas 75032
293.39 mi. away
P: (972) 771-3322

More Details View Practice Page

Prostate Cancer

Clinical Trial at: Texas Oncology - Rockwall

TRITON3: A Multicenter, Randomized, Open-label Phase 3 Study of Rucaparib versus Physician's Choice of Therapy for Patients with Metastatic Castration-resistant Prostate Cancer Associated with Homologous Recombination Deficiency (CO-338-063)

  • Details

ClinicalTrials.gov ID: NCT02975934
Diagnosis Type: NA
USOR Number: 16238

  • Practice Details

3144 Horizon Rd, Suite 110
Rockwall, Texas 75032
293.39 mi. away
P: (972) 771-3322

More Details View Practice Page

Biliary Cancer

Clinical Trial at: Texas Oncology - Dallas

A Phase 3 Multicenter, Open-Label, Randomized, Controlled Study of Oral Infigratinib versus Gemcitabine with Cisplatin in Subjects with Advanced/Metastatic or Inoperable Cholangiocarcinoma with FGFR2 Gene Fusions/Translocations: The PROOF Trial (QBGJ398-301)

  • Details

ClinicalTrials.gov ID: NCT03773302
Diagnosis Type: NA
USOR Number: 18264

  • Practice Details

7777 Forest Lane, Suite D400
Dallas, Texas 75230
294.70 mi. away
P: (972) 566-7790

More Details View Practice Page

Solid Tumors

Clinical Trial at: Texas Oncology - Dallas

(INCB 54828-207) A Phase 2, Open-Label, Single-Arm, Multicenter Study to Evaluate the Efficacy and Safety of Pemigatinib in Participants With Previously Treated Locally Advanced/Metastatic or Surgically Unresectable Solid Tumor Malignancies Harboring Activating FGFR Mutations or Translocations (FIGHT-207)

  • Details

ClinicalTrials.gov ID: NCT03822117
Diagnosis Type: NA
USOR Number: 19079

  • Practice Details

7777 Forest Lane, Suite D400
Dallas, Texas 75230
294.70 mi. away
P: (972) 566-7790

More Details View Practice Page

Leukemia

Clinical Trial at: Texas Oncology - Dallas

A phase 3b study in previously untreated Chronic Lymphocytic Leukemia (CLL) subjects, excluding those with the 17p deletion, to evaluate debulking regimens prior to initiating venetoclax combination therapy (M16-788)

  • Details

ClinicalTrials.gov ID: NCT03406156
Diagnosis Type: CLL
USOR Number: 17106

  • Practice Details

7777 Forest Lane, Suite D400
Dallas, Texas 75230
294.70 mi. away
P: (972) 566-7790

More Details View Practice Page

Lung Cancer

Clinical Trial at: Texas Oncology - Dallas

A Randomized, Double-Blind, Phase 3 Study of Pemetrexed + Platinum Chemotherapy with or without Pembrolizumab (MK-3475) in TKI-resistant EGFR-mutated Tumors in Metastatic Non-squamous Non-small Cell Lung Cancer (NSCLC) Participants (KEYNOTE-789; MK-3475-789)

  • Details

ClinicalTrials.gov ID: NCT03515837
Diagnosis Type: NA
USOR Number: 19020

  • Practice Details

7777 Forest Lane, Suite D400
Dallas, Texas 75230
294.70 mi. away
P: (972) 566-7790

More Details View Practice Page

Leukemia

Clinical Trial at: Texas Oncology - Dallas

A Phase 3, Randomized Study of Zanubrutinib (BGB-3111) Compared with Ibrutinib in Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma (BGB-3111-305)

  • Details

ClinicalTrials.gov ID: NCT03734016
Diagnosis Type: NA
USOR Number: 18155

  • Practice Details

7777 Forest Lane, Suite D400
Dallas, Texas 75230
294.70 mi. away
P: (972) 566-7790

More Details View Practice Page

Lymphomas

Clinical Trial at: Texas Oncology - Dallas

A Phase 3, Randomized Study of Zanubrutinib (BGB-3111) Compared with Ibrutinib in Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma (BGB-3111-305)

  • Details

ClinicalTrials.gov ID: NCT03734016
Diagnosis Type: NA
USOR Number: 18155

  • Practice Details

7777 Forest Lane, Suite D400
Dallas, Texas 75230
294.70 mi. away
P: (972) 566-7790

More Details View Practice Page

Leukemia

Clinical Trial at: Texas Oncology - Dallas

A Phase 3b, Single-Arm, Multicenter Open-Label Study of Venetoclax in Combination with Azacitidine or Decitabine in an Outpatient Setting in AML Patients Ineligible for Intensive Chemotherapy (M19-072)

  • Details

ClinicalTrials.gov ID: NCT03941964
Diagnosis Type: NA
USOR Number: 18168

  • Practice Details

7777 Forest Lane, Suite D400
Dallas, Texas 75230
294.70 mi. away
P: (972) 566-7790

More Details View Practice Page

Lymphomas

Clinical Trial at: Texas Oncology - Dallas

A phase 2 open-label study of brentuximab vedotin in front-line therapy of Hodgkin lymphoma (HL) and CD30-expressing peripheral T-cell lymphoma (PTCL) in adults age 60 and above

  • Details

ClinicalTrials.gov ID: NCT01716806
Diagnosis Type: Hodgkins
USOR Number: 11282

  • Practice Details

7777 Forest Lane, Suite D400
Dallas, Texas 75230
294.70 mi. away
P: (972) 566-7790

More Details View Practice Page

Prostate Cancer

Clinical Trial at: Texas Oncology - Dallas

A Phase 2, Randomized, Double-blind, Placebo-Controlled Study of Abiraterone Acetate Plus Prednisone with or without Abemaciclib in Patients with Metastatic Castration-Resistant Prostate Cancer (I3Y-MC-JPCM)

  • Details

ClinicalTrials.gov ID: NCT03706365
Diagnosis Type: NA
USOR Number: 18128

  • Practice Details

7777 Forest Lane, Suite D400
Dallas, Texas 75230
294.70 mi. away
P: (972) 566-7790

More Details View Practice Page

Lymphomas

Clinical Trial at: Texas Oncology - Dallas

A Multicenter, Randomized, Double-blind, Placebo-controlled Phase 3 Study of the Bruton's Tyrosine Kinase (BTK) Inhibitor, Ibrutinib, in Combination with Rituximab versus Placebo in Combination with Rituximab in Treatment Naïve Subjects with Follicular Lymphoma - PCYC-1141-CA

  • Details

ClinicalTrials.gov ID: NCT02947347
Diagnosis Type: Non-Hodgkins
USOR Number: 16176

  • Practice Details

7777 Forest Lane, Suite D400
Dallas, Texas 75230
294.70 mi. away
P: (972) 566-7790

More Details View Practice Page

Bladder Cancer

Clinical Trial at: Texas Oncology - Dallas

A single-arm, open-label, multicenter study of enfortumab vedotin (ASG-22CE) for treatment of patients with locally advanced or metastatic urothelial cancer who previously received immune checkpoint inhibitor (CPI) therapy - SGN22E-001

  • Details

ClinicalTrials.gov ID: NCT03219333
Diagnosis Type: NA
USOR Number: 17005

  • Practice Details

7777 Forest Lane, Suite D400
Dallas, Texas 75230
294.70 mi. away
P: (972) 566-7790

More Details View Practice Page

Lung Cancer

Clinical Trial at: Texas Oncology - Dallas

Brigatinib in Patients With Anaplastic Lymphoma Kinase-Positive (ALK+), Advanced Non–Small-Cell Lung Cancer (NSCLC) Progressed on Alectinib or Ceritinib (2002)

  • Details

ClinicalTrials.gov ID: NCT03535740
Diagnosis Type: NSCLC
USOR Number: 18076

  • Practice Details

7777 Forest Lane, Suite D400
Dallas, Texas 75230
294.70 mi. away
P: (972) 566-7790

More Details View Practice Page

Urothelial Cancer

Clinical Trial at: Texas Oncology - Dallas

A single-arm, open-label, multicenter study of enfortumab vedotin (ASG-22CE) for treatment of patients with locally advanced or metastatic urothelial cancer who previously received immune checkpoint inhibitor (CPI) therapy - SGN22E-001

  • Details

ClinicalTrials.gov ID: NCT03219333
Diagnosis Type: NA
USOR Number: 17005

  • Practice Details

7777 Forest Lane, Suite D400
Dallas, Texas 75230
294.70 mi. away
P: (972) 566-7790

More Details View Practice Page

Myelofibrosis

Clinical Trial at: Texas Oncology - Dallas

INCB 39110-209, An Open-Label Phase 2 Study of Itacitinib (INCB039110) in Combination With Low-Dose Ruxolitinib or Itacitinib Alone Following Ruxolitinib in Subjects With Myelofibrosis

  • Details

ClinicalTrials.gov ID: NCT03144687
Diagnosis Type: NA
USOR Number: 17085

  • Practice Details

7777 Forest Lane, Suite D400
Dallas, Texas 75230
294.70 mi. away
P: (972) 566-7790

More Details View Practice Page

Prostate Cancer

Clinical Trial at: Texas Oncology - Dallas

TRITON2: A Multicenter, Open-label Phase 2 Study of Rucaparib in Patients with Metastatic Castration-resistant Prostate Cancer Associated with Homologous Recombination Deficiency - CO-338-052

  • Details

ClinicalTrials.gov ID: NCT02952534
Diagnosis Type: NA
USOR Number: 16237

  • Practice Details

7777 Forest Lane, Suite D400
Dallas, Texas 75230
294.70 mi. away
P: (972) 566-7790

More Details View Practice Page

Prostate Cancer

Clinical Trial at: Texas Oncology - Dallas

TRITON3: A Multicenter, Randomized, Open-label Phase 3 Study of Rucaparib versus Physician's Choice of Therapy for Patients with Metastatic Castration-resistant Prostate Cancer Associated with Homologous Recombination Deficiency (CO-338-063)

  • Details

ClinicalTrials.gov ID: NCT02975934
Diagnosis Type: NA
USOR Number: 16238

  • Practice Details

7777 Forest Lane, Suite D400
Dallas, Texas 75230
294.70 mi. away
P: (972) 566-7790

More Details View Practice Page

Pages